Introduction
Adenohypophyseal secretion ofACTH can be elicited by intrinsic and extrinsic stimuli. Many studies have been performed concerning the physiologic, anatomic, and pharmacologic aspects ofthe ACTH regulatory system (1) (2) (3) (4) (5) (6) . These studies support the concept of a complex system subserved by multiple factors of hypothalamic, neurohypophyseal, and peripheral origins (1) . The constellation of putative regulatory factors presently associated with the control network includes corticotropin-releasing factor (CRF)' (7), arginine vasopressin (AVP) (8) , epinephrine (9) , and, possibly, oxytocin (10) . The presence of each of these factors in hypophyseal portal plasma of the rat has been reported (1, 1 1-17) , and high-affinity receptors for CRF (18) , AVP (19), and 1 . Abbreviations used in this paper: AVP, arginine vasopressin; CMF, Hanks' calcium and magnesium-free buffer, CRF, corticotropin-releasing factor; ECM, extracellular matrix; M199/EBSS, medium 199/Earle's balanced salt solution; PGs, prostaglandins; PGE2, prostaglandin E2. epinephrine (20) have been identified in adenohypophyseal tissue. A variety of in vitro and in vivo studies suggest that the action of CRF may be modulated by glucocorticoids (21) (22) (23) (24) (25) (26) (27) (28) , catecholamines (23, 29) , neurohypophyseal peptides (21, 23, (30) (31) (32) , prostaglandins (33) , and other substances.
Therefore, we assessed the ability of human fetal pituitary cells to respond to a variety of substances which have been reported to regulate ACTH secretion in adult animals. Others have suggested that the human fetal pituitary cannot respond to CRF until after 20 wk gestation (34, 35) . However, we have identified human fetal corticotropic cells by the 12th wk of pregnancy, using immunocytochemical techniques (36) ; others have demonstrated the ability of human fetal pituitaries to secrete ACTH by the end of the first trimester (37) . Therefore we sought to ascertain whether the human fetal pituitary could respond to CRF and AVP before 20 wk gestation. To do this, we performed both superfusion and static incubation studies. Superfusion. In the first eight cases, the fetal pituitary was removed and placed in ice-cold medium 199/Earle's balanced salt solution (M199/ EBSS) and transported to the laboratory. Each pituitary was divided into six fragments to increase surface area, placed in a tissue chamber containing superfusion medium, and submerged in a 37°C water bath. The superfusion system was modified from that described by Kraicer and Chow (38) . The Miami, FL) . The effluent from the tissue chamber was collected on ice in sequential 10-min fractions, using a fraction collector (model 328; Isco, Inc., Lincoln, NE). The effluent was divided into three aliquots and stored at -70°C until assay.
Synthetic human CRF was purchased from Peninsula Laboratories (Belmont, CA), dissolved in 10-3 N HCI in normal saline, and slowly injected into the superfusion system (first three superfusions). In the next five superfusions, the CRF was diluted in the superfusion medium within 5 min and equilibrated with O2/CO2 in a reservoir identical to the medium reservoir. It was then superfused as a 10-min square-wave through the peristaltic pump, using the four-way valve to minimize pressure changes.
AVP (Bachem, Torrance, CA) was dissolved in normal saline (pH 4.5) and then diluted in medium. KCI was dissolved in superfusion medium at a concentration of60 mM and administered as a 10-min squarewave at the end of each superfusion.
The purity of CRF and AVP was confirmed by high performance liquid chromatography. CRF was chromatographed on a C-18 column using a flow rate of 1 ml/min and a linear gradient over 40 min from 100% 0.05 M NaH2PO4 to 40% acetonitrile in the phosphate buffer. AVP was analyzed on a C-18 column using the method of O'Hare and Nice (39 (41, 42) . The ECM produced by bovine corneal endothelium has now been used extensively for the culture of various normal and neoplastic cells (43) . Recently, the use of this matrix provided a successful means for culturing human pituitary adenoma cells, which adhere poorly to plastic (41, 42) . The use of ECM can also circumvent the need for various attachment factors in serum (43) (44) (45) . Culture of bovine corneal endothelial cells and the production of ECM were performed according to the method of Gospodarowicz et al. (46) . In brief, for matrix production, stock cultures ofcorneal endothelium were split with saline with 0.1% trypsin and versine, and the corneal endothelial cells (3 X I04'/ml) were plated in 24-well plates with Dulbecco's modified Eagle's medium containing 15% fetal bovine serum, 5% (wt/ vol) dextran T-40, and antibiotics as described above. Fibroblast growth factor (100 ng/ml) was added three times during the first week. After reaching confluence (within 6-7 d), the cultures were incubated for 7-10 additional days, during which time the matrix was deposited. The cells were removed with a rapid wash in 20 mM ammonium hydroxide. The matrix was rinsed twice with phosphate-buffered saline pH 7.4, and the plates containing phosphate-buffered saline and antibiotics were stored at40C.
Pituitary dispersion. Each of the 25 human fetal pituitaries used for static incubations (14-23 wk gestation) was removed within 2 h of pregnancy termination and placed in Hanks' CMF buffer at room temperature. Four term rhesus fetal pituitaries, utilized for comparison, were obtained after hysterotomy. The tissue was minced in fresh Hanks' CMF, and the fragments were transferred to a 15-ml conical tube and centrifuged at 300 g for 1 min. The buffer was aspirated and 5 ml of Hanks' CMF containing 0.5% collagenase and a total of 50 Mg DNAase were added.
This was incubated at 37°C for 1 h in a Dubnoff metabolic shaking incubator (Precision Scientific 66722; American Scientific Products, McGaw Park, IL), after which an additional 50 Mg DNAase were added and the tissue was mechanically dispersed in S ml Hanks' CMF by trituration with a 5 ml pipette. Any remaining fibrous tissue fragments were allowed to settle and were then removed. The cell suspension was centrifuged at 150 g for 5 min, and the cell pellet was resuspended in M 199/ EBSS containing 10% FBS and plated at a density of 7.5-10 X 104 cells per ECM-coated well.
Incubation. After 3-4 d in culture, the cells, by this time firmly attached to the ECM, were washed and preincubated with serum-free medium containing 0.1% BSA. After a 90-min preincubation period, the cells were washed again and secretagogues were added in M 199/EBSS containing 0.1% BSA, penicillin/streptomycin, Hepes buffer, and glutamine; 1 ml per well. Each treatment was performed in quadruplicate or quintuplicate wells. After a 3-h incubation with either medium (control), 10 nM CRF, 10 or 100 nM AVP, or a combination of these secretagogues, the medium was collected in cold polystyrene Eppendorf tubes, aliquoted, and kept at -70°C until assay.
After each incubation, serum-containing medium was added to the cells, which were incubated for 24-48 h. Afterwards the cells were washed and preincubated with serum-free medium, as described above. After preincubation and after 24-48 h incubation, the media were collected and assayed for ACTH to verify that the baseline concentration was the same in all of the wells and that the number of ACTH-secreting cells in each well was comparable. There was no difference between the increase of ACTH secretion after exposure to CRF, AVP, or both on day 3-5 (first experiment) or in subsequent experiments with the same cells.
After the experiments performed with each fetal pituitary, the cells were detached using STV solution and counted, using a Coulter counter (Coulter Electronics Inc., Hialeah, FL).
ACTH radioimmunoassay. The ACTH radioimmunoassay (47) employed rabbit anti-ACTH (1-24) serum, generously provided by Dr. S. Hane, Metabolic Research Unit, UCSF. ACTH (I1-39) (Calbiochem, La Jolla, CA) was used for the standard curve. The ACTH trace supplied by Dr. Hane was iodinated using a modification ofthe method ofHunter and Greenwood (48) .
After a 48-h incubation of samples with antiserum and trace, separation of bound from free hormone was accomplished by addition of goat anti-rabbit y-globulin. The cross-reactivity with alpha melanocytestimulating hormone was <0.1%, and the intraassay and interassay variations were <7.5 and <10%, respectively. The assay sensitivity was (50) .
Results
The addition of CRF to fetal anterior pituitary cells in culture or fragments in superfusion significantly increased ACTH secretion into the medium (Figs. 1 and 2) .
Superfusion ofthe eight 14-23-wk-old human fetal pituitaries resulted in a significant increase in ACTH in the effluent after CRF administration at all ages studied (four less than, and four greater than, 20 wks) (Fig. 2 A and B) . The ability of the tissue to secrete ACTH was confirmed by administration of 60 mM KCI at the end of each superfusion. -_ (Fig. 4) . The combination of 3 mM 8-Br-cAMP with AVP brought about a synergistic effect on ACTH secretion (Fig. 4 ACTH secretion by human fetal pituitary cells, but was less potent than CRF. However, the combination of CRF and 10-7 or 10-8 M AVP was synergistic and induced significantly higher ACTH secretion than that induced by either secretagogue alone (Fig. 1) . The 50% effective concentration of CRF for ACTH secretion was 0.5-1 nM in five different experiments at fetal ages ranging from 17 to 23 wk. A representative example is shown in Fig. 3 . The intrinsic activity (secretory response induced at maximally effective concentrations) of CRF was similar to that of the cAMP derivative, 8-Br-cAMP. Stimulation with 3 mM 8-Br-cAMP in static incubations of dispersed cells (Fig. 4) (Fig. 5) . ACTH secretion in the control wells exposed to medium alone was not significantly different from secretion in the wells exposed to M 199 for 3 h that had been previously exposed to 24-h dexamethasone (n = 5) (Fig. 5) .
In another series of experiments, incubation of fetal pituitary cells with dexamethasone for 3 h did not induce significantly less secretion of ACTH than in control incubations. However, 3-h incubation ofthe cells with dexamethasone and CRF induced significantly lower ACTH secretion than that induced by 3-h exposure to CRF alone (n = 5) (Fig. 6) . The effects of exposure to dexamethasone with CRF, AVP, or other secretagogues were completely reversed 24 h after removal ofthe steroid by multiple medium changes.
Interaction between CRF and catecholamines. The a-or ,Badrenergic agonists, norepinephrine, or isoproterenol ( 10-6 M), did not result in significant change in ACTH secretion (n = 5). There was no change in ACTH secretion after a 3-h exposure to catecholamines alone or to a combination of catecholamines and CRF or AVP, compared with CRF or AVP alone (n = 5).
Interaction between CRF andprostaglandin or indomethacin. Exposure of fetal pituitary cells to prostaglandin E1 (10-6 M; n = 4) or to prostaglandin E2 (PGE2) (10-6 M; n = 3) did not result in any significant change in ACTH secretion compared with that of control cells, either alone or in combination with CRF or AVP. Similarly, 3-h ., dexamethasone. Least square means±SEM. ***P < 0.001. **P <0.01. The similar effects of CRF and cAMP derivatives and the ACTH-releasing actions ofagents known to elevate intracellular cAMP, such as phosphodiesterase inhibitors, cholera toxin, and forskolin, have suggested an involvement ofthe adenylate cyclase system in ACTH secretion (23, 27, 51, 52) . CRF was found to rapidly elevate intracellular cAMP levels in rat anterior pituitary cell cultures, and glucocorticoid pretreatment markedly inhibited CRF-mediated increases in intracellular cAMP concentrations (27, 28) . This was thought to indicate that the glucocorticoid effect might be mediated by altered cAMP levels. Our observation that glucocorticoids can inhibit ACTH secretion brought about by exogenous 8-Br-cAMP in human fetal pituitary cells suggests that glucocorticoids also act, in part, beyond the cAMP-generating step in their inhibition of CRF action.
The synergistic effects of AVP and CRF and of AVP and 8-Br-cAMP, but not ofCRF and 8-Br-cAMP, on ACTH secretion by human fetal pituitary cells are consonant with the hypothesis that there are different second messengers involved in the cellular actions of CRF and AVP (53) . Whereas CRF action on ACTH release is mediated by the adenylate cyclase-protein kinase pathway, AVP action on ACTH release is modulated by a cAMPindependent mechanism that appears to be initiated by a rise in cytosolic calcium concentration (53) .
Oxytocin was found to be an ACTH secretagogue and to act synergistically with CRF in rat pituitary cells in one study (27 (33) , PGE2 was found to be formed locally, after binding of the neurohormones, and to act as a negative feedback-modulator ofvasopressin and CRF activity in the anterior pituitary gland. Our findings that PGs or indomethacin alone or in combination with CRF or AVP do not stimulate or inhibit ACTH secretion are similar to previous studies in rats (58) . Although PGs may have a physiologic role in modulating ACTH secretion in the adult, this ability may not develop until late in intrauterine, or early in extrauterine, life.
We did not find a significant correlation between fetal age and the ACTH response to CRF or to CRF + AVP between 14 and 23 wk of human gestation, nor between the response of these second trimester human pituitary cells and the response of four rhesus term fetal pituitary cells. A correlation with age, however, has been found in sheep fetuses (59, 60) at a gestational age comparable to 28-34 wk in humans, a stage not amenable to testing in the human fetus.
The ontogenesis of the corticotrophs and their response to CRF, AVP, and glucocorticoids occurs before the 14th wk of fetal life. The response to catecholamines and prostaglandins may develop later in intra-or extrauterine life. In any case, the human fetal pituitary has the capacity to respond to stress stimuli in utero by the beginning of the second trimester of pregnancy. As previously reported (1, 2, 8, 15, 16, (21) (22) (23) (24) (25) (26) 32) , the responses to stress stimuli consist mainly of regulation ofACTH secretion by CRF and AVP and feedback by adrenal glucocorticoids. Our studies in the human fetus demonstrate that the capacity for all of these responses exists at or before 14 wk of intrauterine life.
A drawback of static incubation is the inability to assess precisely the time course ofchanges in hormonal secretion after exposure to a releasing factor or other modulator of secretion. The combination of superfusion and static incubation may be complimentary in understanding the complex interactions of various modulators of fetal pituitary hormone synthesis and secretion.
